Kallyope Rebranded as TriGemX Bio Following $94M Raise
The company has pivoted to focus on its migraine drug elismetrep after selling its obesity programs to Novo Nordisk.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you support pharmaceutical firms shifting investment from metabolic disease treatments toward new neurological drugs?
Kallyope has rebranded as TriGemX Bio and secured $94 million in new financing to advance its oral migraine candidate, elismetrep, into Phase III clinical trials. This strategic shift follows the sale of three obesity programs to Novo Nordisk earlier this year.
Why it matters
The company shifted its pipeline focus toward neurology after reporting disappointing obesity data in early 2025. By targeting the trigeminal ganglion, the renamed firm aims to capture a share of the migraine therapeutic market.
In a Phase IIb study of 431 adults, the 20 mg dose of elismetrep achieved a 17.6% 2-hour pain freedom rate versus 9.1% for placebo. The study also recorded a 58.8% pain relief rate, compared to 42.4% in the placebo group.
The players
TriGemX Bio
A biotechnology company focused on neurology that specializes in oral TRPM8 channel blockers.
Novo Nordisk
A global pharmaceutical firm with a significant portfolio in diabetes and obesity treatments.
The details
Elismetrep functions as a TRPM8 channel blocker, which is a protein receptor that plays a role in sensory signaling. The company is using a liquid-filled soft-gel formulation designed to accelerate drug absorption in the gut. The name TriGemX Bio references the trigeminal ganglion, a neural structure associated with the pathophysiology of migraine.
Timeline
Early 2025: Company reported disappointing obesity data.
April 2026: Company announced an improved soft-gel formulation.
October 1, 2026: Company announced its rebranding and $94 million financing.
October 2026: Expected start of a second pivotal trial.
Mid-2027: Anticipated results from the first Phase III trial.
The Tech Race
TriGemX Bio is advancing elismetrep through the competitive landscape of next-generation migraine therapies targeting the trigeminal ganglion. The success of this transition now hinges on the start of a second pivotal trial to confirm these initial findings.
Patients will not see immediate changes as the drug remains in clinical development. Success in upcoming trials is required before the drug can be reviewed for public availability or therapeutic prescription.
The takeaway
The company has transitioned its primary focus to migraine treatment following the offloading of its metabolic programs. Stakeholders should monitor the start of the second pivotal trial scheduled for October 2026 for evidence of continued progress.
What happens next
The company expects to initiate a second pivotal trial in October 2026, with the first Phase III trial results anticipated by mid-2027.
Further reading
For broader trends in neurology research, explore the latest updates in Biotech.
Live Poll
Do you support pharmaceutical firms shifting investment from metabolic disease treatments toward new neurological drugs?
